Millions Against Monsanto: Ruling, Roundup Suits, and $7.25B Settlement

On June 25, 2026, the U.S. Supreme Court ruled 7-2 in Monsanto Co. v. Durnell that federal pesticide law blocks state-court failure-to-warn lawsuits over Roundup, reversing a $1.25 million Missouri verdict and dismantling the legal theory behind most of the roughly 200,000 cancer claims tied to the herbicide. The Roundup lawsuit Supreme Court ruling means that plaintiffs can no longer sue Monsanto for failing to put a cancer warning on Roundup’s label, because the Environmental Protection Agency reviewed glyphosate, decided no such warning was required, and federal law does not permit states to demand a different one.¹

For people with pending claims, or who were considering filing one, the practical effect is stark. The failure-to-warn theory was the backbone of nearly every Roundup case. That door is now closed. A separate $7.25 billion class settlement, awaiting final approval in a Missouri state court, is the main remaining path to compensation.

What the Court Decided

Justice Brett Kavanaugh wrote the majority opinion, joined by Chief Justice Roberts and Justices Thomas, Alito, Sotomayor, Kagan, and Barrett. The Court held that the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) expressly preempts state failure-to-warn claims that would force a pesticide maker to add a cancer warning the EPA has not required.¹

The reasoning is straightforward. FIFRA requires the EPA to approve every pesticide label before the product goes to market. Once approved, the manufacturer must use that exact label and faces civil and criminal penalties for changing it. FIFRA’s “Uniformity” clause then bars states from imposing labeling requirements “in addition to or different from” federal requirements. A state jury telling Monsanto it should have added a cancer warning is imposing a different requirement, and the statute preempts it.¹

The majority leaned heavily on Riegel v. Medtronic, Inc. (2008), where the Court held that FDA premarket approval of a medical device preempted state claims demanding different safety features. FIFRA’s preemption clause, the Court said, is “nearly identical,” so EPA registration must do the same work.¹

The ruling also resolved a split among federal appeals courts. The Ninth and Eleventh Circuits had allowed Roundup failure-to-warn claims to proceed; the Third Circuit had blocked them. The Third Circuit’s position is now the law nationwide.¹

The Case Behind the Ruling

John Durnell sued Monsanto in Missouri state court in 2019, alleging that about 20 years of using Roundup caused his non-Hodgkin’s lymphoma. A jury awarded him $1.25 million on his failure-to-warn claim. The same jury rejected his separate claims for defective design and negligence. Missouri’s trial and appellate courts refused to find the verdict preempted. The Supreme Court agreed to hear the case in January 2026, held oral arguments on April 27, and reversed.²

The Dissent

Justice Ketanji Brown Jackson, joined by Justice Neil Gorsuch, called the ruling “both remarkable and regrettable.” She argued that EPA approval of a label does not conclusively establish that a product is properly labeled under FIFRA, because the statute separately forbids selling a pesticide whose label lacks warnings adequate to protect health. She also read the statute to let states impose requirements “equivalent to” federal misbranding rules, meaning a cancer-warning duty could coexist with FIFRA rather than conflict with it. Jackson emphasized that the ruling leaves plaintiffs like Durnell with no legal remedy for injuries they allege were caused by an inadequately labeled product.³

Justice Thomas joined the majority but wrote separately to suggest that FIFRA itself “likely exceeds Congress’s authority under the Commerce Clause” and to question whether delegating labeling authority to the EPA improperly transfers legislative power. His concerns did not change the outcome.³

What Happens to Pending Roundup Lawsuits

As of early 2026, roughly 3,900 Roundup cases sat in the federal multidistrict litigation in the Northern District of California, and tens of thousands more were pending in state courts.⁴ Bayer said the ruling should produce dismissals of current warnings-based claims and “foreclose future claims based on state-failure-to-warn theories,” which the company called the “vast majority” of its litigation exposure.⁵

Stanford Law professor Robert Rabin wrote that the ruling “dispatches not just Durnell’s suit, but many thousands of other outstanding, similar claims,” while noting collateral issues around the MDL and the pending settlement.⁶

The opinion does not directly address design defect or negligence claims. In Durnell’s case the jury had already rejected those theories, so the Court had no reason to rule on them. Whether plaintiffs can rebuild their cases around alternative theories is unsettled, and the practical obstacles are real: a design defect claim aimed at a pesticide whose formulation is effectively fixed by EPA registration faces its own preemption problems.

Prior bellwether verdicts that fueled the litigation, including the $80 million Hardeman award affirmed by the Ninth Circuit in 2021 and Bayer’s pending appeal of the $2.065 billion Barnes verdict from Georgia in March 2025, rested on the same failure-to-warn reasoning the Supreme Court has now rejected.⁷⁸ Whether verdicts still on appeal survive is now an open question tied to how each was framed at trial.

The $7.25 Billion Class Settlement

One week before oral arguments in Durnell, Bayer filed a proposed nationwide class settlement worth up to $7.25 billion in a St. Louis, Missouri, state court on February 17, 2026. The company has described the settlement and the Supreme Court win as “independently necessary and mutually reinforcing.” With failure-to-warn claims preempted, claimants who opt out to sue on their own now face a legal landscape where the most viable theory of liability is gone.⁹⁵

Who the Settlement Covers

The settlement covers people who were exposed to Roundup before February 17, 2026, and who have been diagnosed with non-Hodgkin’s lymphoma or who receive that diagnosis within 16 years of final court approval. Monsanto would fund the settlement through declining annual payments over 17 to 21 years. Individual payouts are tiered by exposure type, cancer severity, and age at diagnosis. Occupational claimants may receive $60,000 to $165,000, while residential users would average $20,000 to $40,000. Bayer does not admit liability.¹⁰⁹

Where the Settlement Stands

A Missouri judge granted preliminary approval in March 2026. The opt-out deadline passed on June 4, 2026, and a final approval hearing is set for July 9, 2026. More than 100 class members and 12 health care companies filed objections, and objectors tried unsuccessfully to move the case to federal court before it was sent back to state court on June 17, 2026. Federal MDL Judge Vince Chhabria, who described the procedural handling of the deal as “dirty,” declined to intervene and said challenges belonged in the Missouri Court of Appeals or the state Supreme Court.¹¹

What the Ruling Does Not Touch

The decision addresses only failure-to-warn claims under FIFRA. It does not resolve every piece of Bayer’s Monsanto-related litigation. Bayer is separately appealing more than $1.5 billion in verdicts from Washington state tied to polychlorinated biphenyls (PCBs), which are governed by a different regulatory scheme and are not affected by Durnell.¹²

Preemption analysis is also case-specific, as Professor Rabin noted: the ruling is a major preemption decision for this mass tort, but future disputes in other regulatory contexts will require their own inquiry into how clearly the relevant federal agency has spoken.⁶

What to Do If You Have a Roundup Claim

If you have a pending Roundup failure-to-warn lawsuit, expect a motion to dismiss on preemption grounds, if one has not already been filed. Talk to your attorney about whether any part of your case rests on design defect, negligence, or other theories that were not directly decided in Durnell, and how those theories fare under EPA registration.

If you have a non-Hodgkin’s lymphoma diagnosis linked to Roundup exposure and did not opt out of the class settlement by June 4, 2026, you are presumptively covered by the proposed settlement, subject to final court approval on July 9, 2026. The settlement’s tiered structure and long claim window (16 years from final approval for future diagnoses) mean the terms matter even for people not yet diagnosed.¹⁰

If you opted out planning to sue independently, the legal ground has shifted underneath that decision. The failure-to-warn theory that produced the largest verdicts against Monsanto no longer exists as a viable claim, and the alternative theories left standing have not been tested at the Supreme Court under the framework Durnell establishes.

1
Supreme Court of the United States. Monsanto Co. v. Durnell, No. 24-1068
2
Mayer Brown. Supreme Court Holds Roundup Failure-to-Warn Claim Preempted by Federal Law
3
SCOTUSblog. Court Rules for Roundup Maker in Dispute Over Cancer Warnings on Pesticide Labels
4
MDL Update. Roundup Products Liability Litigation MDL-2741
5
Bayer. Monsanto Wins Landmark Roundup Case at US Supreme Court
6
Stanford Law School. Thoughts on Monsanto Co. v. Durnell
7
U.S. Court of Appeals for the Ninth Circuit. Hardeman v. Monsanto Co., Nos. 19-16636, 19-16708
8
CNN. Bayer Ordered to Pay $2 Billion in Roundup Lawsuit
9
Reuters. Bayer Makes $7.25 Billion Push to Settle Roundup Cases
10
Bayer. Monsanto Announces Roundup Class Settlement Agreement
11
The Daily Record. Judge Sends Bayer Roundup Settlement Back to State Court
12
Bloomberg Law. Bayer Hit With $857 Million Verdict on Toxic Monsanto Chemicals